Ever Fortune AI Obtains Approval for Listing in Vietnam Market
Ever Fortune AI (6841-TW) announced today (October 4th) that three of its products – the cardiac-thoracic ratio estimation system, pneumothorax detection system, and pleural effusion detection system – have received approval for listing from the Vietnam Ministry of Health. In addition, their gene testing risk assessment method has also been granted a patent in Japan.
Ever Fortune AI stated that the cardiac-thoracic ratio estimation system is capable of automatically distinguishing between posteroanterior chest X-ray images and automatically marking lines for the maximum heart diameter and maximum thoracic cavity diameter. This enables the calculation of the cardiac-thoracic ratio value. The structured report includes patient information, image capture date, compressed posteroanterior chest X-ray images, marked lines for the heart and thoracic cavity, cardiac-thoracic ratio values, and a historical trend chart of cardiac-thoracic ratio values, simplifying the operation time for clinical physicians.
The pneumothorax detection system, on the other hand, can automatically analyze chest X-ray images taken in the posteroanterior position that comply with the DICOM 3.0 standard. It identifies features indicative of pneumothorax and provides priority sorting and alert markers through PACS/workstation. This allows radiologists to review patients potentially showing signs of pneumothorax earlier than the standard clinical procedure, expediting the clinical radiological workflow.
As for the pleural effusion detection system, it automatically analyzes posteroanterior chest X-ray images of adult patients to determine whether they exhibit characteristics of pleural effusion. The analysis results can be transmitted to PACS/workstation for prioritized sorting or categorization in the worklist and provide alerts. With this product, radiologists can review patients with signs of pleural effusion earlier than the standard clinical procedure, speeding up the clinical radiological workflow.
Ever Fortune AI stated that Vietnam, as a crucial economic and cultural hub in the Southeast Asian region with nearly a hundred million people, has experienced continuous population growth in recent years. This growth has led to a significant increase in the demand for healthcare services. With an aging population and an increased awareness of health, the need for high-quality and efficient healthcare services has become increasingly urgent.
Furthermore, Ever Fortune AI ‘s gene testing risk assessment method has obtained a patent in Japan. This patent uses multiple genes as variables, combining probability theory with disease prevalence rates in different countries to calculate risk threshold values. This approach ensures that disease risk assessment aligns more closely with semantics.
Refer to the original post here
For additional details, refer to our SIA services | Link
